Management of neuropathy and foot problems in diabetic patients

Clinical Cornerstone

Volumn 5, Issue 2, 2003, Pages 38-55

  Vinik, Aaron I ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIOXIDANT; AZATHIOPRINE; CALCITONIN; CALCIUM CHANNEL BLOCKING AGENT; CAPSAICIN; CARBAMAZEPINE; CLONIDINE; DEXTROMETHORPHAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GABAPENTIN; GAMMA LINOLENIC ACID; IMMUNOGLOBULIN; INSULIN; LIDOCAINE; MEXILETINE; NORTRIPTYLINE; ORAL ANTIDIABETIC AGENT; PHENYTOIN; PLACEBO; PREDNISONE; SEROTONIN UPTAKE INHIBITOR; SUBSTANCE P; THIOCTIC ACID; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

AMPUTATION; ANAMNESIS; ANAPHYLAXIS; ANTICHOLINERGIC EFFECT; ARTICLE; AUTONOMIC NEUROPATHY; BLOOD FLOW; CLINICAL FEATURE; CLINICAL TRIAL; DEVELOPED COUNTRY; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC FOOT; DIABETIC NEUROPATHY; DYSAUTONOMIA; ELECTROPHYSIOLOGY; GANGRENE; HEADACHE; HUMAN; MORTALITY; MOTOR NEUROPATHY; NERVE FIBER; NERVE INJURY; NEUROPATHIC JOINT DISEASE; PATIENT EDUCATION; PERIPHERAL NEUROPATHY; PHYSICAL EXAMINATION; POLYNEUROPATHY; QUALITY OF LIFE; RISK; SENSORY NEUROPATHY; SIDE EFFECT; SYNDROME; XEROSTOMIA;

EID: 0037978924     PISSN: 10983597     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1098-3597(03)90017-2     Document Type: Article

References (66)

1. Vinik AI, Mitchell BD, Leichter SB, et al. Epidemiology of the complications of diabetes. In: Leslie RDG, Robbins DC, eds. Diabetes: Clinical Science in Practice. Cambridge, United Kingdom: Cambridge University Press; 1995:221-287.
2. Holzer SE, Camerota A, Martens L, et al. Costs and duration of care for lower extremity ulcers in patients with diabetes. Clin Ther. 1998;20: 169-181.
3. Caputo GM, Cavanagh PR, Ulbrecht JS, et al. Assessment and management of foot disease in patients with diabetes. N Engl J Med. 1994;331: 854-860.
4. Young MJ, Boulton AJM, MacLeod AF, et al. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia. 1993;36:1-5.
5. Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: The Rochester Diabetic Neuropathy Study. Neurology. 1993;43:817-824.
6. Vinik A. Diabetic neuropathy: Pathogenesis and therapy. Am J Med. 1999;107:17S-26S.
7. Armstrong DG, Lavery LA, Harkless LB. Validation of a diabetic wound classification system. The contribution of depth, infection, and ischemia to risk of amputation. Diabetes Care. 1998;21:855-859.
8. Levitt NS, Stansberry KB, Wynchank S, Vinik AI. The natural progression of autonomic neuropathy and autonomic function tests in a cohort of IDDM. Diabetes Care. 1996;19:751-754.
9. Rathmann W, Ziegler D, Jahnke M, et al. Mortality in diabetic patients with cardiovascular autonomic neuropathy. Diabet Med. 1993;10:820-824.
10. Consensus Statement. Report and recommendations of the San Antonio conference on diabetic neuropathy. American Diabetes Association; American Academy of Neurology. Diabetes Care. 1988;11: 592-597.
11. Vinik AI, Park TS, Stansberry KB, Pittenger GL. Diabetic neuropathies. Diabetologia. 2000;43: 957-973.
12. Vinik AI, Holland MT, LeBeau JM, et al. Diabetic neuropathies. Diabetes Care. 1992;15:1926-1975.
13. Dawson DM. Entrapment neuropathies of the upper extremities. N Engl J Med. 1993;329: 2013-2018.
14. Vinik A. Diagnosis and management of diabetic neuropathy. Clin Geriatr Med. 1999;15:293-320.
15. Bird SJ, Brown MJ. The clinical spectrum of diabetic neuropathy. Semin Neurol. 1996;16:115-122.
16. Hanson P, Schumacker P, Debugne T, Clerin M. Evaluation of somatic and autonomic small fibers neuropathy in diabetes. Am J Phys Med Rehabil. 1992;71:44-47.
17. Tesfaye S, Malik R, Harris N, et al. Arterio-venous shunting and proliferating new vessels in acute painful neuropathy of rapid glycaemic control (insulin neuritis). Diabetologia. 1996;39:329-335.
18. van Heel DA, Levitt NS, Winter TA. Diabetic neuropathic cachexia: The importance of positive recognition and early nutritional support. Int J Clin Pract. 1998;52:591-592.
19. Holland NR, Crawford TO, Hauer P, et al. Small-fiber sensory neuropathies: Clinical course and neuropathology of idiopathic cases. Ann Neurol. 1998;44:47-59.
20. Said G, Bigo A, Ameri A, et al. Uncommon early-onset neuropathy in diabetic patients. J Neurol. 1998;245:61-68.
21. Vinik AI. Diagnosis and management of diabetic neuropathy. Can J Diabetes Care. 2000;24:56-76.
22. Dyck PJ. Detection, characterization, and staging of polyneuropathy: Assessed in diabetics. Muscle Nerve. 1988;11:21-32.
23. Vinik AI, Mitchell B. Clinical aspects of diabetic neuropathies. Diabetes Metab Rev. 1988;4: 223-253.
24. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia. 1995;38:1425-1433.
25. Feldman EL, Stevens MJ, Thomas PK, et al. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. 1994; 17:1281-1289.
26. Vinik AI, Newlon P, Milicevic Z, et al. Diabetic neuropathies: An overview of clinical aspects. In: LeRoith D, Taylor SI, Olefsky JM, eds. Diabetes Mellitus: A Fundamental and Clinical Text. Philadelphia, Pa: Lippincott-Raven; 1996: 737-750.
27. Vinik AI, Suwanwalaikorn S, Stansberry KB, et al. Quantitative measurement of cutaneous perception in diabetic neuropathy. Muscle Nerve. 1995;18: 574-584.
28. Ducher M, Cerutti C, Gustin MP, et al. Noninvasive exploration of cardiac autonomic neuropathy. Four reliable methods for diabetes? Diabetes Care. 1999;22:388-393.
29. Said G, Goulon-Goeau C, Lacroix C, Moulonguet A. Nerve biopsy findings in different patterns of proximal diabetic neuropathy. Ann Neurol. 1994; 35:559-569.
30. Jaradeh SS, Prieto TE, Lobeck LJ. Progressive polyradiculoneuropathy in diabetes: Correlation of variables and clinical outcome after immunotherapy. J Neurol Neurosurg Psychiatry. 1999;67: 607-612.
31. Kennedy WR, Wendelschafer-Crabb G, Johnson T. Quantitation of epidermal nerves in diabetic neuropathy. Neurology. 1996;47:1042-1048.
32. Periquet MI, Novak V, Collins MP, et al. Painful sensory neuropathy: Prospective evaluation using skin biopsy. Neurology. 1999;53:1641-1647.
33. Krendel DA, Zacharias A, Younger DS. Autoimmune diabetic neuropathy. Neurol Clin. 1997; 15:959-971.
34. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
35. Pirart J. Diabetes mellitus and its degenerative complications: A prospective study of 4,400 patients observed between 1947 and 1973 (3rd and last part) (author's transl) [in French]. Diabete Metab. 1977;3:245-256.
36. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998; 352:854-865.
37. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
38. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-713.
39. Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: The Steno type 2 randomised study. Lancet. 1999;353:617-622.
40. Ziegler D, Schatz H, Conrad F, et al. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie. Diabetes Care. 1997;20:369-373.
41. Ziegler D, Gries FA. Alpha-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy. Diabetes. 1997;46(Suppl 2):S62-S66.
42. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: A 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care. 1999;22:1296-1301.
43. Jamal GA. The use of gamma linolenic acid in the prevention and treatment of diabetic neuropathy. Diabet Med. 1994;11:145-149.
44. Keen H, Payan J, Allawi J, et al. Treatment of diabetic neuropathy with gamma-linolenic acid. The gamma-Linolenic Acid Multicenter Trial Group. Diabetes Care. 1993;16:8-15.
45. Krendel DA, Costigan DA, Hopkins LC. Successful treatment of neuropathies in patients with diabetes mellitus. Arch Neurol. 1995;52:1053-1061.
46. Barada A, Reljanovic M, Milicevic Z, et al. Proximal diabetic neuropathy-response to immunotherapy [abstract]. Diabetes. 1999;48 (Suppl 1):A148. 0639.
47. Suez D. Intravenous immunoglobulin therapy: Indications, potential side effects, and treatment guidelines. J Intraven Nurs. 1995;18:178-190.
48. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: An update and effect related to mechanism of drug action. Pain. 1999;83:389-400.
49. Rains C, Bryson HM. Topical capsaicin. A review of its pharmacological properties and therapeutic potential in post-herpetic neuralgia, diabetic neuropathy and osteoarthritis. Drugs Aging. 1995;7: 317-328.
50. Byas-Smith MG, Max MB, Muir J, Kingman A. Transdermal clonidine compared to placebo in painful diabetic neuropathy using a two-stage 'enriched enrollment' design. Pain. 1995;60: 267-274.
51. Jarvis B, Coukell AJ. Mexiletine. A review of its therapeutic use in painful diabetic neuropathy. Drugs. 1998;56:691-707.
52. Harati Y, Gooch C, Swenson M, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology. 1998;50: 1842-1846.
53. Nelson KA, Park KM, Robinovitz E, et al. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology. 1997;48:1212-1218.
54. Max MB, Lynch SA, Muir J, et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med. 1992;326: 1250-1256.
55. McQuay H, Carroll D, Jadad AR, et al. Anti-convulsant drugs for management of pain: A systematic review. BMJ. 1995;311:1047-1052.
56. Gorson KC, Schott C, Herman R, et al. Gabapentin in the treatment of painful diabetic neuropathy: A placebo controlled, double blind, crossover trial. J Neural Neurosurg Psychiatry. 1999;66:251-252.
57. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: A randomized controlled trial. JAMA. 1998; 280:1831-1836.
58. Vinik A, Fonseca V, LaMoreaux L, et al. Neurontin (gabapentin, GBP) improves quality of life (QOL) in patients with painful diabetic peripheral neuropathy [abstract]. Diabetes. 1998;47(Suppl 1):A374. 6-13.
59. Somers DL, Somers MF. Treatment of neuropathic pain in a patient with diabetic neuropathy using transcutaneous electrical nerve stimulation applied to the skin of the lumbar region. Phys Ther. 1999;79:767-775.
60. Zieleniewski W. Calcitonin nasal spray for painful diabetic neuropathy. Lancet. 1990;336:449.
61. Cavanagh PR, Derr JA, Ulbrecht JS, et al. Problems with gait and posture in neuropathic patients with insulin-dependent diabetes mellitus. Diabet Med. 1992;9:469-474.
62. Nelson ME, Fiatarone MA, Morganti CM, et al. Effects of high-intensity strength training on multiple risk factors for osteoporotic fractures. A randomized controlled trial. JAMA. 1994;272: 1909-1914.
63. NIDDK. Diabetic neuropathies: The nerve damage of diabetes. Website. 2002. Available at: http//www.niddk.nih.gov/health/diabetes/pubs/neuro/neuro.htm. Accessed February 21, 2003.
64. Groner C. Advances in glucose control benefit foot care. BioMechanics. 1998;5:7-15.
65. American Diabetes Association. Clinical Practice Recommendations 2003. Diabetes Care. 2003; 26(Suppl 1):S1-S155.
66. Rith-Najarian S, Reiber G. Prevention of foot problems in persons with diabetes. J Fam Pract. 2000; 49(11 Suppl):S30-S39.